TrialAmerican journal of hematology2016

A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).

Clive S Zent et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.